Advanced in Clear Cell Sarcoma

Dr. Robert M. Graham

Hematology Oncology | Hematology | Oncology
Tennessee Oncology PLLC
605 Glenwood Dr, Suite 200, 
Chattanooga, TN 
Accepting New Patients
Offers Telehealth
Advanced in Clear Cell Sarcoma
Tennessee Oncology PLLC
605 Glenwood Dr, Suite 200, 
Chattanooga, TN 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Robert Graham is a Hematologist Oncology specialist and a Hematologist in Chattanooga, Tennessee. Dr. Graham is rated as an Advanced provider by MediFind in the treatment of Clear Cell Sarcoma. His top areas of expertise are Childhood Iron Deficiency Anemia, Familial Pancreatic Cancer, Paget Disease of the Breast, and Dehydration. Dr. Graham is currently accepting new patients.

His clinical research consists of co-authoring 2 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in GA
Hospital Affiliations
Parkridge Medical Center
Memorial Healthcare System, Inc
Erlanger Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alliant Health
  • HMO
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Farm Bureau Health Plans
  • HMO
  • MEDICARE MAPD
  • MEDICARE PDP
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
US Health and Life
  • EPO
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 17 Less Insurance Carriers -

Locations

TENNESSEE ONCOLOGY PLLC
605 Glenwood Dr, Suite 200, Chattanooga, TN 37404

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Enrollment Status: Completed
Publish Date: September 15, 2022
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1/2 Study of Pegzilarginase (AEB1102, Co-ArgI-PEG) in Combination With Pembrolizumab in the Treatment of Patients With Extensive Disease (ED) Small Cell Lung Cancer (SCLC)
A Phase 1/2 Study of Pegzilarginase (AEB1102, Co-ArgI-PEG) in Combination With Pembrolizumab in the Treatment of Patients With Extensive Disease (ED) Small Cell Lung Cancer (SCLC)
Enrollment Status: Completed
Publish Date: November 04, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
An Open-label, Multi-center, Expanded Treatment Protocol (ETP) of Oral LDK378 in Adult Patients With Non-small Cell Lung Cancer (NSCLC) Characterized by ALK Positivity
An Open-label, Multi-center, Expanded Treatment Protocol (ETP) of Oral LDK378 in Adult Patients With Non-small Cell Lung Cancer (NSCLC) Characterized by ALK Positivity
Enrollment Status: No_longer_available
Publish Date: November 03, 2020
Intervention Type: Drug
Randomized Study of AM0010 in Combination With FOLFOX Compared to FOLFOX Alone as Second-line Tx in Pts With Metastatic Pancreatic Cancer That Has Progressed During or Following a First-Line Gemcitabine Containing Regimen
Randomized Study of AM0010 in Combination With FOLFOX Compared to FOLFOX Alone as Second-line Tx in Pts With Metastatic Pancreatic Cancer That Has Progressed During or Following a First-Line Gemcitabine Containing Regimen
Enrollment Status: Completed
Publish Date: October 19, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 3
An Open-label, Multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in Adult Patients With Newly Diagnosed Fms-like Tyrosine Kinase Receptor (FLT3) Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for Standard Induction and Consolidation Chemotherapy.
An Open-label, Multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in Adult Patients With Newly Diagnosed Fms-like Tyrosine Kinase Receptor (FLT3) Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for Standard Induction and Consolidation Chemotherapy.
Enrollment Status: No_longer_available
Publish Date: July 15, 2020
Intervention Type: Drug
View 4 Less Clinical Trials

2 Total Publications

BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer.
BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 15, 2021
Similar Doctors
Distinguished in Clear Cell Sarcoma
Dr. Hosam M. Saad-Naguib
Hematology Oncology | Hematology | Oncology
Distinguished in Clear Cell Sarcoma
Dr. Hosam M. Saad-Naguib
Hematology Oncology | Hematology | Oncology

Tennessee Oncology PLLC

1504 N Thornton Ave, Suite 102, 
Dalton, GA 
 (23.2 miles away)
706-226-0508
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Hosam Saad-Naguib is a Hematologist Oncology specialist and a Hematologist in Dalton, Georgia. Dr. Saad-Naguib is rated as a Distinguished provider by MediFind in the treatment of Clear Cell Sarcoma. His top areas of expertise are Monoclonal Gammopathy of Undetermined Significance (MGUS), Colorectal Cancer, Familial Colorectal Cancer, and Pleuropulmonary Blastoma. Dr. Saad-Naguib is currently accepting new patients.

Distinguished in Clear Cell Sarcoma
Dr. Davey B. Daniel
Hematology Oncology | Hematology | Oncology
Distinguished in Clear Cell Sarcoma
Dr. Davey B. Daniel
Hematology Oncology | Hematology | Oncology

Tennessee Oncology PLLC

4645 Battlefield Pkwy, 
Ringgold, GA 
 (8.6 miles away)
423-648-2362
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Davey Daniel is a Hematologist Oncology specialist and a Hematologist in Ringgold, Georgia. Dr. Daniel is rated as a Distinguished provider by MediFind in the treatment of Clear Cell Sarcoma. His top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Dehydration, and Non-Small Cell Lung Cancer (NSCLC). Dr. Daniel is currently accepting new patients.

Advanced in Clear Cell Sarcoma
Dr. Edward R. Arrowsmith
Hematology Oncology | Hematology | Oncology
Advanced in Clear Cell Sarcoma
Dr. Edward R. Arrowsmith
Hematology Oncology | Hematology | Oncology

Tennessee Oncology PLLC

2333 Mccallie Ave, 
Chattanooga, TN 
 (0.6 miles away)
423-493-1690
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Edward Arrowsmith is a Hematologist Oncology specialist and a Hematologist in Chattanooga, Tennessee. Dr. Arrowsmith is rated as a Distinguished provider by MediFind in the treatment of Clear Cell Sarcoma. His top areas of expertise are Pleuropulmonary Blastoma, Lung Cancer, Dehydration, and Familial Colorectal Cancer. Dr. Arrowsmith is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Graham's expertise for a condition
ConditionClose
    View All 80 Advanced Conditions
    View All 171 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile